BRIEF-Teva collaborates with Intel to develop a device for use in huntington disease

Thu Sep 15, 2016 8:22am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

Sept 15 (Reuters) - Teva Pharmaceutical Ltd Says It Will Deploy The Technology Platform In A Sub

* Teva Pharmaceutical announces collaboration with Intel Corp to develop a unique wearable device and machine learning platform for use in huntington disease

* Study within ongoing Phase 2 Open-Pride HD study

* Says study will start towards end of year and will take place in centers in U.S and Canada Source text for Eikon: Further company coverage: